Adipotide (FTPP) — selective inducer of adipocyte apoptosis
In short
Targeted peptide studied in animal models for selectively inducing apoptosis in the vasculature of white adipose tissue.
Overview
Adipotide (Prohibitin‑TP01) is a chimeric, adipose‑vasculature–targeted peptidomimetic that homes to prohibitin/annexin A2 on white adipose tissue endothelium and delivers a pro‑apoptotic D‑(KLAKLAK)2 motif. In obese primates it produced rapid fat loss with improved insulin resistance, but development halted after an early Phase 1 oncology trial; kidney safety signals (reversible proximal tubule changes) remain a key concern.
CKGGRAKDC homes to prohibitin/annexin A2 on white‑fat endothelium; the linked D‑(KLAKLAK)2 disrupts mitochondrial membranes after internalization, triggering localized endothelial apoptosis and adipocyte loss.
Molecular information
Research indications
Grouped by area. Each entry reflects a separate published hypothesis or clinical signal - not medical advice.
Barnhart et al. (Sci Transl Med 2011) - 0.43 mg/kg s.c. daily for 28 days reduces white adipose mass by 11% in obese rhesus monkeys.
Не е одобрен от . Предназначен е само за изследователски и образователни цели. Проследявайте серумния креатинин, BUN, анализа на урината и електролитите ежеседмично при проучвания върху животни. При примати се наблюдават дозозависими и предимно обратими промени в проксималните тубули на бъбреците. Избягвайте дехидратация. Обмислете временно спиране при трайно повишаване на креатинина. Не е проучван при бременност и кърмене. Спрете при трайно повишаване на креатинина или олигурия. Прекратете при прогресивни електролитни аномалии. Спрете при тежки реакции на мястото на инжектиране или системни симптоми. При всяка неочаквана токсичност спрете и направете оценка.
3 peer-reviewed sources
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
Barnhart Phase 1
Animal | 0.43 mg/kg s.c. | 28 days | -11% white adipose mass
Sci Transl Med · 2011
View the studyInformation about Adipotide is based on published scientific research and is intended for research purposes only. Not medical advice.
Products are for in vitro laboratory research only. Not approved for human consumption.
Other peptides
5-Amino-1MQ
5-Amino-1MQ is a small-molecule selective inhibitor of NNMT (nicotinamide N-methyltransferase), identified by Anthony Sauve (Cornell) in 2018. NNMT is a "metabolic sink" for methyl donors and NAD+ — suppressing it in adipocytes raises energy expenditure without reducing calorie intake.
ReadAOD-9604
AOD-9604 is a modified C-terminal 16-amino-acid fragment of human growth hormone (177-191), supplemented with a tyrosine residue. Retains the lipolytic effect of the full molecule but without diabetogenic or GH-stimulating activity. Developed by Metabolic Pharmaceuticals (Australia) in the 1990s.
ReadARA-290
ARA-290 (Cibinetide) is an 11-amino-acid fragment of erythropoietin (EPO) developed by Anthony Cerami as a cytoprotective molecule without erythropoietic activity. It retains the tissue-protective effects of EPO without raising hematocrit — explaining its potential in diabetic neuropathy and cardiac applications.
ReadArgireline
Argireline is a synthetic acetylated hexapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) derived from SNAP-25 — the SNARE complex subunit mediating acetylcholine release at neuromuscular junctions. Topical application reduces muscle activity in expression areas — which is why Argireline is marketed as a "topical Botox alternative".
ReadBPC-157
BPC-157 is a 15-amino-acid fragment isolated from a protective protein in human gastric juice — hence the name Body Protection Compound. Over thirty years of research by Predrag Sikiric's group at the University of Zagreb (100+ peer-reviewed papers) establish its angiogenic action through the VEGFR2 receptor and its stimulation of fibroblasts. If you work with in vitro models of tendon, muscle or gut tissue, BPC-157 is among the most extensively documented regenerative peptides.
ReadCagrilintide
Cagrilintide is a modified amylin analog developed by Novo Nordisk as a partner to semaglutide in combined incretin-amylin therapy. CagriSema (cagrilintide + semaglutide) showed 17.1% body-weight reduction in Phase 2 — a promising next step over semaglutide alone.
ReadNo comments yet. Be the first.
Comments are reviewed before publishing.
